Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Recommendation of "Reduce" by Brokerages

Key Points

• Seres Therapeutics, Inc. (NASDAQ:MCRB) has received an average rating of "Reduce" from five brokerages, with three analysts recommending a sell.
• The average 12-month price target for Seres Therapeutics is $14.33, with Canaccord Genuity recently increasing its target to $22.00 and assigning a buy rating.
• The stock has experienced a price fluctuation over the past year, with a low of $6.53 and a high of $24.67, and it currently trades at $20.59.

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) have been given an average rating of "Reduce" by the five ratings firms that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $14.3333.

MCRB has been the topic of several analyst reports. Weiss Ratings reissued a "sell (d+)" rating on shares of Seres Therapeutics in a research note on Saturday, September 27th. Canaccord Genuity Group boosted their price target on Seres Therapeutics from $14.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, September 24th.

Hedge Funds Weigh In On Seres Therapeutics

A number of large investors have recently bought and sold shares of MCRB. Vontobel Holding Ltd. increased its position in shares of Seres Therapeutics by 15.7% during the first quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after purchasing an additional 147,671 shares in the last quarter. Marshall Wace LLP purchased a new stake in Seres Therapeutics in the second quarter valued at $1,016,000. Invesco Ltd. boosted its holdings in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 89,995 shares during the last quarter. SBI Securities Co. Ltd. boosted its holdings in Seres Therapeutics by 221.8% in the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 48,013 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 37,866 shares in the last quarter. Institutional investors own 59.34% of the company's stock.

Seres Therapeutics Price Performance

Shares of MCRB stock traded down $0.45 during trading hours on Friday, hitting $20.59. The stock had a trading volume of 264,845 shares, compared to its average volume of 268,113. Seres Therapeutics has a one year low of $6.53 and a one year high of $24.67. The stock's 50-day moving average price is $17.40 and its two-hundred day moving average price is $12.65. The stock has a market capitalization of $180.16 million, a price-to-earnings ratio of -4.48 and a beta of 0.19.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.72) by $0.45. As a group, equities research analysts predict that Seres Therapeutics will post -0.38 earnings per share for the current fiscal year.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.